Drugs / E.coli Double Mutant Heat-Labile Toxin
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04232943 | Jan 2020 → Feb 2021 | poliomyelitis | PATH | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | E.coli Double Mutant Heat-Labile Toxin | “E.coli Double Mutant Heat-Labile Toxin (dmLT) (adjuvant)” NCT04232943 ↗ |
| Known as | dmLT | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04232943 ↗ |
| Modality | Protein / enzyme biologic | “LT (R192G/L211A), or "dmLT," is a protein toxoid” NCT04232943 ↗ |